Topcat study spironolactone

Author: nxwb

August undefined, 2024

Web10. jan 2024 · TOPCAT tested spironolactone, a generically available agent, amplifying the potential global public health impact that would come with a favorable ﬁnding. However, … Web19. jún 2024 · The lack of an effect of spironolactone on the prevention of new-onset AF or AF recurrence in this study may be due to the neutral primary results concerning HF outcomes in the TOPCAT trial. Indeed, TOPCAT investigators stratified patients to AF or no AF at baseline and found no differential effect of spironolactone or placebo on the main …

Spironolactone in Patients With Heart Failure ... - ScienceDirect

Web27. jan 2024 · In 2013 the TOPCAT investigators tried to proof similar efficacy in patients with heart failure and preserved ejection fraction (≥ 45%). Because of regional variations in the enrollment process and difficulties regarding drug adherence the trial revealed neutral findings but the substance spironolactone was still able to show its potential ... Web18. nov 2013 · The TOPCAT trial showed that spironolactone is not superior to placebo in improving CV outcomes in patients with HFpEF, with higher rates of hyperkalemia and … radisson myyntipalvelu

Spironolactone in Patients With Heart Failure, Preserved Ejection ...

WebSupplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone ... WebObjective: The TOPCAT trial is designed to evaluate the effect of spironolactone, an aldosterone antagonist, on morbidity, mortality, and quality of life in patients with HF-PEF. … Web10. apr 2014 · We therefore initiated the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial to determine whether treatment … The fact that spironolactone significantly reduced the risk of both morbidity and … radisson monterrey san jeronimo

Supplementary Appendix - The New England Journal of Medicine

Risk Stratification and Efficacy of Spironolactone in ... - Springer

Web24. máj 2024 · In the randomized, placebo-controlled TOPCAT study of spironolactone in patients with heart failure (HF) and preserved left ventricular ejection fraction, spironolactone showed no benefit for the primary outcome of cardiovascular death, HF hospitalization, and cardiac arrest (NEJM JW Cardiol May 2014 and N Engl J Med 2014; … Web9. mar 2024 · TOPCAT was a multinational, double-blind, randomized, placebo-controlled, parallel-group study that investigated the effects of the mineralocorticoid receptor antagonist (MRA) spironolactone versus placebo on clinical outcomes in patients with HFpEF. The rationale and design of the study have been previously published (2 or serum … cynthia nontellWeb8. aug 2024 · Spironolactone has been regarded as a promising medication for the treatment of HFpEF because of its observed positive effects on the cellular, serum biomarker, and echocardiographic level. 10 - 13 In the TOPCAT trial, patients with HFpEF were randomized to spironolactone versus placebo, and no significant difference in the … radisson sas palais hotel vienna

"Web29. mar 2024 · This study randomized patients with HFpEF and either prior hospitalization for HF or elevated NP levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo. Of the 3,445 patients enrolled in the TOPCAT trial, 2,464 (72%) were enrolled in the hospitalization stratum and 981 (28%) in the elevated NP stratum. " - Topcat study spironolactone

Topcat study spironolactone

Regional variation in patients and outcomes in the Treatment of ...

Web9. mar 2024 · Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function: Published in: Journal of the American College of Cardiology, 77(9), 1211 - 1221. ELSEVIER SCIENCE INC. ISSN 0735-1097. Author Web10. jan 2024 · TOPCAT tested spironolactone, a generically available agent, amplifying the potential global public health impact that would come with a favorable ﬁnding. However, it must also be acknowledged that the approximately $30 million allotted to TOPCAT was far less than the $200 to 300 mil-lion operating budget of a comparable industry-sponsored …

Did you know?

Web27. apr 2024 · In a subgroup of TOPCAT participants assigned to spironolactone, the spironolactone metabolite canrenone was measured to assess adherence. Canrenone levels were undetectable in 30% of... Web16. nov 2024 · TOPCAT study design and objectives. The design of the TOPCAT study has been described in detail previously. 10 Briefly, TOPCAT was a multi-centre, international, randomized, double blinded, placebo-controlled trial of spironolactone in adults with HFpEF recruited from over 270 clinical sites. The trial was funded by the National Heart, Lung ...

Web27. jan 2024 · In 2013 the TOPCAT investigators tried to proof similar efficacy in patients with heart failure and preserved ejection fraction (≥ 45%). Because of regional variations … Web4. apr 2024 · Taken together with other reported regional differences in the TOPCAT trial, the results of the current study arouse concerns regarding study conduct at some sites in Russia and, by implication, Georgia, where event rates and responses to spironolactone were also of concern (Table S3 in the Supplementary Appendix). 2 Our findings suggest that ...

Web21. nov 2016 · Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial … WebTOPCAT: Spironolactone vs. placebo for the treatment of heart failure with preserved ejection fraction 1 FDA Briefing Document Cardiovascular and Renal Drugs Advisory …

WebEmerging data that show novel potassium binders reducing the risk of hyperkalemia may further facilitate such a study. 10 Spironolactone is a prodrug that is converted to active metabolite canrenone, which is responsible for its mineralocorticoid effects. 15 Considering that the mean duration of AHF hospitalization in the United States is 4 to ...

WebRecently, the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study, a randomized, double-blind clinical trial of spironolactone … radisson san jose airport parkingWeb10. apr 2014 · with an Aldosterone Antagonist (TOPCAT) trial to determine whether treatment with spironolactone would improve clinical outcomes in patients with … radisson paulista hotelWeb10. apr 2014 · Lessons from the TOPCAT Trial NEJM Home Specialties Specialties Allergy/ Immunology Cardiology Clinical Medicine Dermatology Emergency Medicine Endocrinology Gastroenterology Genetics... cynthia paola castorela cruzWeb9. mar 2024 · Background: Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization … radisson vakancesWeb1. mar 2024 · TOPCAT was a multinational, double-blind, randomized, placebo-controlled, parallel-group study that investigated the effects of the mineralocorticoid receptor antagonist (MRA) spironolactone versus placebo on clinical outcomes in patients with HFpEF. The rationale and design of the study have been previously published ( 11 ). cynthia medina carsonWeb10. apr 2014 · TOPCAT is a multi-center, international, randomized, double-blind, placebo-controlled trial of the aldosterone antagonist, spironolactone, in 3,445 adult subjects with heart failure and left ... cynthia pattonWeb2. mar 2024 · Die TOPCAT-Studie (Spironolacton versus Placebo) hat zwar den primären Endpunkt (kardialer Tod oder HIH) verfehlt, ihre Daten haben jedoch darauf hingewiesen, dass Spironolacton das Auftreten von HIH verhindern könnte. 10 Es gibt jedoch in den europäischen Leitlinien zur Behandlung der Herzinsuffizienz keine Empfehlung für den … radisson santa maria